Understanding where GLP-1 uptake is booming, where it is stalling, and why, offers important insight into how the obesity treatment revolution is reshaping global healthcare systems
Those on semaglutide in the latest trial lost an average of 9.4 percent of their body weight compared with people taking the placebo, who lost less than 1 percent
Anyone starting semaglutidewhether compounded through a licensed 503A pharmacy or brandedshould verify expiration dates upon delivery, confirm refrigeration equipment is functional, and discuss storage questions with their provider or pharmacy
These medications are a tool to help a teenager reach a better state of health, and thats what we really should be looking at not the scales
75% of GLP-1 users believe they'll still be on their treatment plan a year from now
For over-50s, even modest reductions can translate into meaningful changes in movement and quality of life